


Clinical Difference Between Fibroblast Growth Factor Receptor 2 Subclass, Type IIIb and Type IIIc, in Gastric Cancer

Masakazu Yashiro^{1,2,3}, Kenji Kuroda^{1,2}, Go Masuda^{1,2}, Tomohisa Okuno^{1,2}, Yuichiro Miki^{1,2}, Yurie Yamamoto¹, Tomohiro Sera^{1,2}, Atsushi Sugimoto^{1,2}, Shuhei Kushiya^{1,2}, Sadaaki Nishimura^{1,2}, Shingo Togano^{1,2}, and Masaichi Ohira²

¹ Molecular Oncology and Therapeutics, Osaka City University Graduate School of Medicine. ² Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine. ³ Cancer Center for Translational Research, Osaka City University Graduate School of Medicine, Osaka, Japan



Supplement figure 1. Representative pictures of staining by mFR2-10b and mFR2-28c on FGFR2IIIb and FGFR2IIIc overexpression cells. The recombinant chimeric antibodies of mFR2-10b and mouse mFR2-28c recognized FGFR2IIIb and FGFR2IIIc overexpression cells, respectively, but not other FGFR overexpression cells.